A new study by Brigham Young University researchers on the virus behind
nearly half of all cold infections explains how and where evolution
occurs in the rhinovirus genome and what this means for possible
"There are a lot of different approaches to treating the cold, none
of which seem to be effective," said Keith Crandall, professor of
biology and co-author of the study. "This is partly because we haven’t
spent a lot of time studying the virus and its history to see how it’s
responding to the human immune system and drugs."
The BYU team studied genomic sequences available online and used
computer algorithms to estimate how the rhinovirus is related to other
According to Nicole Lewis-Rogers, a postdoctoral fellow in the
Biology Department and lead author on the study, the rhinovirus is
similar to the polio virus, whose vaccine was announced in 1955. But
while the polio virus has just three subspecies, the rhinovirus has
more than 100 subspecies, which continually evolve.
"These viruses could be under the same constraints and yet change
differently," Lewis-Rogers said. "That’s why it is so hard to create a
Through a computer program developed at BYU, Lewis-Rogers’ team was
able to identify the parts of the virus genome that enable resistance
to drugs and the human immune system.
The immune system does a good job of recognizing viral contaminants
and getting rid of them, as do new drugs, but the rhinovirus has
responded to these defenses by changing its genome so that it is not so
"The virus is evolving solutions against the immune system and
drugs," Crandall said. "The more we can learn about how the virus
evolves solutions, the better we can rid the body of these infections."
Understanding where change occurs in the virus genome will help virologists who work to design drugs that target the rhinovirus.
"If you’ve got 10,000 bits of information, this narrows it down to a
handful," Lewis-Rogers said. "Here is where you can start looking."
Lewis-Rogers and Crandall hope scientists will use these insights to
build better drugs to combat the virus in the most effective way.
The study is reported in the April issue of the journal Molecular Biology and Evolution. BYU
undergraduate Matthew Bendall is also a co-author on the study, which
was funded by the USDA. Bendall will next pursue a master’s in
bioinformatics at BYU.
Source : Brigham Young University